Eight chemical structures not previously reported to possess antifilarial activity have been identified. A total of 79 compounds with anticancer properties were evaluated for possible macrofilaricidal activity against Brugia pahangi and Acanthocheilonema viteae transplanted into male Mongolian jirds (Meriones unguiculatus). All eight active compounds were suppressive for the onchocerciasis type (Acanthocheilonema viteae) of the disease. None was macrofilaricidal for the lymphatic form (Brugia pahangi). These new structures may represent a nucleus around which effective drugs can be synthesized.
References
1.
World Health Organization.World Health Organization Progress Report. Division of Control of Tropical Diseases, Geneva, 1997.
2.
World Health Organization.Prospects for Elimination of Chagas Disease, Leporsy, Lymphatic Filariasis, Onchocerciasis. TDR/Gen/97.1, Geneva, 1997.
3.
BacikovaD, BetinaV, NemecP.Antinematodal Activity of the antibiotic Cyanein. Naturwissenschaften51: 445, 1964.
4.
KinnamonKE, SteckEA, RaneDS. Activity of antitumor drugs against African trypanosomes. Antimicrob Agents Chemother15: 157–160, 1979.
5.
KinnamonKE, SteckEA, RaneDS. Anticancer agents and antitrypanosomiasis activity in mice. J Natl Cancer Inst64: 391–394, 1980.
6.
KinnamonKE, PoonBT, HansonWL, WaitsVB. Activity of anticancer compounds against Trypanosoma cruzi-infected mice. Am J Trop Med Hyg58: 804–806, 1998.
7.
BockmanRW, ThompsonJR, BellMJ, SkipperGJ. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res16: 167–170, 1956.
8.
DrainDJ, GoodacreCL, SeymoreD.Para-aminosalicylic acid-Part III: Some further studies on the in vitro tuberculostatic behavior of paraaminosalicylic acid and related compounds. J Pharm Pharmacol1: 784–787, 1949.
9.
LoganJC, FoxMP, MorganJH, MakohonAM, PfauCJ. Arenavirus inactivation on contact with N-substituted isatin β-thiosemicarbazones and certain cations. J Gen Virol28: 271–283, 1975.
10.
WinkelmannE, WagnerWH, WirthH.Anticoccidial activity of dithiosemicarbazones. Arzneimittelforschung27: 950–967, 1977.
11.
KlaymanDL, BartovichJF, GriffinTS, MasonCJ, ScovillJP. 2-Acetylpyridine thiosemicarbazones. I: A new class of potential antimalarial agents. J Med Chem22: 855–862, 1979.
12.
KlaymanDL, LinAJ, McCallJW, WangSY, TownsonS, GrogolM, KinnamonKE. 2-Acetylpyridine thiosemicarbazones. 13: Derivatives with antifilarial activity. J Med Chem34: 1422–1425, 1991.
13.
RoseWC, CrosswellAR, BronsonJJ, MartinJC. In vivo antitumor activity of 9-[2-phosphonylmethoxy) ethyl]-guanine and related phosphonate nucleotide analogues. J Natl Cancer Inst82: 510–512, 1990.
14.
KovachJS, SvingenPA, SchaldDJ. Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. J Natl Cancer Inst84: 515–519, 1992.
15.
SteinCA, LaRoccaRV, ThomasR, McAteeN, MyersCE. Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol7: 499–508, 1989.
RenouxG.The general immunopharmacology of levamisole. Drugs20: 89–136, 1980.
18.
World Health Organization Report.Eleventh Meeting of the Scientific Working Group on Filariasis: Review of Filaricide Screening Methods and Results in Relation to Synthetic Chemistry, Biochemistry, and Toxicology. Geneva, Switzerland, March 11–14, 1985.
19.
GoodwinLG. Chemotherapy. Trans R Soc Trop Med Hyg78 (Suppl): 1–8, 1984.
20.
KinnamonKE, KlaymanDL, PoonBT, McCallJW, DzimianskiMT, RowanSJ. Filariasis testing in a jird model: New drug leads from some old standbys. Am J Trop Med Hyg51: 791–796, 1994.
21.
McCallJW. The role of arthropods in the development of animal models for filariasis research. J Georgia Ent Soc16: 283–293, 1981.
22.
JohnsonMH, OrihelTC, BeaverPC. Dipetalonema viteae in the experimentally infected jird, Meriones unguiculatus. 1. Insemination, development from egg to microfilaria, reinsemination, and longevity of mated and unmated worms. J Parasitol60: 302–309, 1974.
23.
BacchiCJ, NathanHC, YarlettN, GoldbergB, McCannPP, BitontiAJ, SjoerdsmaA.Cure of murine Trypanosoma brucei rhodesiense infections with an S-adenosylmethionine decarboxylase inhibitor. Antimicrob Agents Chemother36: 2736–2740, 1992.
24.
GingerCD. Filarial worms: Targets for drugs. Parasitol Today7: 262–264, 1991.
25.
Special Programme for Research and Training in Tropical Diseases. WHO Division of Control of Tropical Diseases, UNDP/WORLD BANK/WHO, World Health Organization, Geneva, Switzerland, 1990.
26.
World Health Organization.Common leads and targets in the chemotherapy of kinetoplastidae, malaria, and filaria. World Health Organization Meeting, Geneva, Switzerland, January 28–29, 1993.
27.
TaylorCW, LuiR, FantaP, SalmonSE. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst84: 489–494, 1992.
28.
PandyaU, ShuklaOP. Suramin destabilises the secondary structure of filarial DNA. Med Sci Res22: 833–834, 1994.
29.
GingerCD. Molecular/biochemical development of new drugs against macro- and microfilariae. Acta Leiden59: 315–328, 1990.
30.
WalterRD, Schulz-KayH.Onchocerca volvulus: Effect of suramin on lactate dehydrogenase and malate dehydrogenase. Tropenmed Parasitol31: 55–58, 1980.
31.
WalterRD, AlbiezEJ. Inhibition of NADP-linked malic enzyme from Onchocerca volvulus and Dirofilaria immilis by suramin. Mol Biochem Parasitol4: 53–60, 1981.
32.
RenzA, TreesAJ, Achu-KwlD, EdwardsG, WahlG.Evaluation of suramin, ivermectin, and CGP 20376 in a new macrofilaricidal drug screen, Onchocerca ochengi in African cattle. Trop Med Parasitol46: 31–37, 1995.
33.
CrossHF, BronsvoortBM, WahlG, RenzA, Achu-KwiD, TreesAJ. The entry of ivermectin and suramin into Onchocerca ochengi nodules. Ann Trop Med Parasitol91: 393–401, 1997.
34.
WalterRD. Polyamine metabolism of filaria and allied parasites. Parasitol Today4: 19–20, 1988.
35.
WalterRD. Polyamine metabolism of filaria as a target for chemotherapy. Meeting on ‘Targets for New Macrofilaricides,” Geneva, Switzerland, 1991.
36.
HartwellLH, SzankasiP, RobertsCJ, MurrayAW, FriendSH. Integrating genetic approaches into the discovery of anticancer drugs. Science278: 1064–1068, 1997.
